Searching across hundreds of databases

Our searching services are busy right now. Your search will reload in five seconds.

X
Forgot Password

If you have forgotten your password you can enter your email here and get a temporary password sent to your email.

X
Forgot Password

If you have forgotten your password you can enter your email here and get a temporary password sent to your email.

Sequencing methods and datasets to improve functional interpretation of sleeping beauty mutagenesis screens.

BMC genomics | 2014

Animal models of cancer are useful to generate complementary datasets for comparison to human tumor data. Insertional mutagenesis screens, such as those utilizing the Sleeping Beauty (SB) transposon system, provide a model that recapitulates the spontaneous development and progression of human disease. This approach has been widely used to model a variety of cancers in mice. Comprehensive mutation profiles are generated for individual tumors through amplification of transposon insertion sites followed by high-throughput sequencing. Subsequent statistical analyses identify common insertion sites (CISs), which are predicted to be functionally involved in tumorigenesis. Current methods utilized for SB insertion site analysis have some significant limitations. For one, they do not account for transposon footprints - a class of mutation generated following transposon remobilization. Existing methods also discard quantitative sequence data due to uncertainty regarding the extent to which it accurately reflects mutation abundance within a heterogeneous tumor. Additionally, computational analyses generally assume that all potential insertion sites have an equal probability of being detected under non-selective conditions, an assumption without sufficient relevant data. The goal of our study was to address these potential confounding factors in order to enhance functional interpretation of insertion site data from tumors.

Pubmed ID: 25526783 RIS Download

Research resources used in this publication

None found

Additional research tools detected in this publication

Antibodies used in this publication

None found

Associated grants

  • Agency: NCI NIH HHS, United States
    Id: R21CA170195
  • Agency: NHLBI NIH HHS, United States
    Id: T32 HL007344
  • Agency: NEI NIH HHS, United States
    Id: R01EY023187
  • Agency: NCI NIH HHS, United States
    Id: R01CA132962
  • Agency: NCI NIH HHS, United States
    Id: P30 CA086862
  • Agency: NEI NIH HHS, United States
    Id: R01 EY023187
  • Agency: NCI NIH HHS, United States
    Id: R01 CA132962
  • Agency: NCI NIH HHS, United States
    Id: R21 CA170195
  • Agency: NHLBI NIH HHS, United States
    Id: HL007344
  • Agency: NIGMS NIH HHS, United States
    Id: T32 GM008629

Publication data is provided by the National Library of Medicine ® and PubMed ®. Data is retrieved from PubMed ® on a weekly schedule. For terms and conditions see the National Library of Medicine Terms and Conditions.

This is a list of tools and resources that we have found mentioned in this publication.


Illumina (tool)

RRID:SCR_010233

American company incorporated that develops, manufactures and markets integrated systems for the analysis of genetic variation and biological function. Provides a line of products and services that serve the sequencing, genotyping and gene expression and proteomics markets. Its headquarters are located in San Diego, California.

View all literature mentions

B6.129-Gt(ROSA)26Sortm1(cre/ERT2)Tyj/J (tool)

RRID:IMSR_JAX:008463

Mus musculus with name B6.129-Gt(ROSA)26Sortm1(cre/ERT2)Tyj/J from IMSR.

View all literature mentions